0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-157.73%PremiumMay 16, 2025Expiry Date4.59Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.65Leverage Ratio--Theta--Rho--Eff Leverage--Vega
MaxCyte Stock Discussion
Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment
MaxCyte (MXCT) has entered into a strategic platform license agreement with TG Therapeutics for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The partnership aims to support the development and commercialization of azer-cel, TG's allogeneic CD19 CAR T cell therapy program for autoimmune diseases.
Under the agreement, TG Therapeutics re...
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte (Nasdaq: MXCT; LSE: MXCT) and Kamau Therapeutics have entered a strategic platform license agreement. Kamau gains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes. In return, MaxCyte will receive annual licensing fees and program-related revenu...
NEWS
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive an...
Larger Image: tradingview.com...
$MaxCyte (MXCT.US)$
• $Antares Pharma (ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology (SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma (AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $BriaCell Therapeutics (BCTX.US)$ +6% (presents development details of...
No comment yet